|

enfortumab vedotin Clinical Trials

32 actively recruiting trials across 21 locations

▲ +1 trial since May 2026

Also known as: AGS 22ME, AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE +12 more

Pipeline

Phase 1: 2Phase 2: 19Phase 3: 1Phase 4: 2Phase 1/2: 5Phase 2/3: 1

Top Sponsors

  • Astellas Pharma Global Development, Inc.4
  • Memorial Sloan Kettering Cancer Center3
  • Mayo Clinic3
  • National Cancer Institute (NCI)2
  • Emory University2

Indications

  • Cancer32
  • Urothelial Carcinoma4
  • Metastatic Urothelial Carcinoma4
  • Bladder Cancer3
  • Urothelial Cancer3

Other6 trials

Tucson, Arizona2 trials

Duarte, California2 trials

Atlanta, Georgia2 trials

Rochester, Minnesota2 trials

Basking Ridge, New Jersey2 trials

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Phoenix, Arizona1 trial

Fayetteville, Arkansas1 trial

Little Rock, Arkansas1 trial

Los Angeles, California1 trial

San Francisco, California1 trial

Santa Monica, California1 trial

Washington D.C., District of Columbia1 trial

Renal Retention in High Grade Upper Tract Urothelial Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2

Miami, Florida1 trial

Tampa, Florida1 trial

Bethesda, Maryland1 trial

Ann Arbor, Michigan1 trial

Hackensack, New Jersey1 trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1/2

Philadelphia, Pennsylvania1 trial

Austin, Texas1 trial

Dallas, Texas1 trial

Houston, Texas1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.